Travere TherapeuticsTVTX
TVTX
About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Employees: 385
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
609% more call options, than puts
Call options by funds: $27.4M | Put options by funds: $3.86M
12% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 67
2.13% more ownership
Funds ownership: 110.44% [Q1] → 112.57% (+2.13%) [Q2]
6% less funds holding
Funds holding: 217 [Q1] → 205 (-12) [Q2]
16% less capital invested
Capital invested by funds: $1.77B [Q1] → $1.48B (-$292M) [Q2]
17% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 47
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
74%
upside
Avg. target
$31
80%
upside
High target
$32
86%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Greg Harrison | 80%upside $31 | Sector Outperform Maintained | 7 Aug 2025 |
Wedbush Laura Chico | 86%upside $32 | Outperform Maintained | 7 Aug 2025 |
HC Wainwright & Co. Joseph Pantginis | 74%upside $30 | Buy Assumed | 1 Jul 2025 |
Citigroup Carly Kenselaar | 86%upside $32 | Buy Maintained | 11 Jun 2025 |
HC Wainwright & Co. Ed Arce | 74%upside $30 | Buy Assumed | 11 Jun 2025 |
Financial journalist opinion
Based on 8 articles about TVTX published over the past 30 days
Positive
Seeking Alpha
2 weeks ago
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore
Travere Therapeutics has successfully executed a significant restructuring to recover from previous setbacks and improve its financial health. It has built a compact pipeline of kidney therapy drugs with several having blockbuster potential. Its approved FILSPARI in treatment of IgAN is enjoying rapid growth.
Neutral
Business Wire
2 weeks ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 45,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted a.
Neutral
Seeking Alpha
2 weeks ago
Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Christopher Cline - Chief Financial Officer Eric M. Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Nivi Nehra - Corporate Participant e - Corporate Participant V - Corporate Participant i - Corporate Participant c - Corporate Participant P - Corporate Participant r - Corporate Participant e - Corporate Participant s - Corporate Participant i - Corporate Participant d - Corporate Participant Communications & Investor Relations - Corporate Participant e - Corporate Participant n - Corporate Participant t - Corporate Participant o - Corporate Participant f - Corporate Participant o - Corporate Participant r - Corporate Participant p - Corporate Participant o - Corporate Participant r - Corporate Participant a - Corporate Participant t - Corporate Participant e - Corporate Participant Peter Heerma - Chief Commercial Officer William E.
Positive
Zacks Investment Research
2 weeks ago
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
2 weeks ago
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.9 per share a year ago.
Neutral
Business Wire
2 weeks ago
Travere Therapeutics Reports Second Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its second quarter 2025 financial results and provided a corporate update. “We continue to make strong progress against our strategic priorities, putting Travere on a trajectory for both near- and long-term growth. This quarter marked our strongest commercial performance to date, with increased momentum for FILSPARI resulting in significant growth in a dynamic IgAN market,” said Eric Dube, Ph.D., president and.
Neutral
Business Wire
2 weeks ago
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET Citi's 2025 Biopharma Back to School Conference Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET 2025 Wells Fargo Healthcare Conference Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET Cantor Global.
Neutral
Business Wire
3 weeks ago
Travere Therapeutics to Report Second Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentation.
Neutral
Business Wire
1 month ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 17 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 121,700 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as i.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™